Tradestie Institutional Equity Comparison Engine
ARTV vs CDT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ARTV Overall Edge
ARTV Captures Institutional Edge (2โ0 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Artiva Biotherapeutics, Inc. Common Stock (ARTV) driven by superior Momentum & Technical, Options & Structure. Fundamentally, ARTV trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ARTV sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ARTV N/M vs CDT N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner
ARTV
1Y +11.5% vs -86.8% ยท 52W Pos 7% vs 2%
Options & Structure Winner
ARTV
BREAKDOWN (<1st %ile IV) vs BREAKDOWN (N/A IV)
ARTV
NASDAQ
Artiva Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.78
-1.31% 1D
Market Cap
$189.3M
1M Return
-39.03%
1Y Return
+11.5%
Forward P/E
N/M
Unified AI Score
54.0 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 63.0
Mom 59.0
CDT
NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap
$507,528
1M Return
+76.79%
1Y Return
-86.78%
Forward P/E
N/M
Unified AI Score
31.6 / 100
SELL
Tech 15.0
Fund 37.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ARTV +11.5%
CDT -86.78%
Spread: +98.28 pp (ARTV Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ARTV TTM Op. Margin: 0.0%
CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARTV vs CDT. Trailing 12-month operating profitability (ARTV 0.0% vs CDT 0.0%) and valuation multiples (ARTV N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ARTV | CDT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $189.3M | $507,528 | Larger Scale | ARTV |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +0.0% | Higher Growth | CDT |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -43.6% | -69.7% | Higher ROE | ARTV |
| 52-Week Range Position Momentum | 7% ($3โ$15) | 2% ($0โ$11) | Stronger Trend | ARTV |
| Beta / 30D Volatility Risk Regime | 1.52ฮฒ ยท 104% Vol | -17.75ฮฒ ยท 10175% Vol | Lower Realized Risk | ARTV |
| Unified Institutional Score Composite Signal | 54.0 / 100 (HOLD) | 31.6 / 100 (SELL) | Higher Composite | ARTV |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ARTV vs CDT Buy Guide
ARTV
BREAKDOWN
150d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
CDT
BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ARTV nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.